Grifols, a global healthcare company and producer of plasma therapies, has signed an agreement to acquire the transfusion diagnostics unit of Novartis for a total of $1.7 billion. The transaction is part of Grifols’ growth strategy for its plasma protein therapies with other diagnostic products and services.   Grifols expands its portfolio with Novartis’ diagnostic products for transfusion medicine and immunology, including its NAT technology (Nucleic Acid Amplification Techniques), ...